Tungsten is a unique transition metal owing to its high melting point, conductivity, strength and flexibility. These traits make it an indispensible part of modern life involved in everything from household goods, such as light bulbs and golf clubs, to technologically advanced materials. Until recently, tungsten was considered as a relatively inert metal; however, several investigations suggest that tungsten may have carcinogenic properties. Tungsten exposure has been linked to several leukemia clusters, including the well-publicized one in Fallon, Nevada, as well as Sierra Vista, Arizona and Elk Grove, California. [1] [2] [3] These populations undoubtedly had multiple potential exposures, but the contribution of tungsten to the generation of leukemia is unknown.
Tungsten-associated toxicities have been evaluated in a small number of studies. Tungsten altered stimulated cytokine profiles in a human monocytic leukemia cell line. 4 In addition, exposure of mature human peripheral blood lymphocytes to tungsten caused an increase in apoptosis and altered cell growth. 4 Heavy metal-tungsten alloys increased the tumorigenicity of a nontumorigenic human osteoblast-like cell line in vitro and tumor incidence in nude mice. 5 Embedded tungsten alloy fragments (also containing nickel and cobalt) induced rhabdomyosarcoma tumors in rats within a year, 6 but there is no information regarding the contribution of tungsten alone in this study.
Tungsten enters the body through ingestion or inhalation and can circulate via the blood. It is rapidly excreted, but some tungsten remains in the kidney, liver, spleen and bone. 7 During chronic exposure, a steady-state level of tungsten is reached in the body, except in the bone, where it may continue to increase during the lifetime. 7 Developing bone may also accumulate more tungsten than mature bone. 7 This accumulation of tungsten within the bone may result in higher exposure levels within the bone marrow, which contains part of the developing immune system.
Most of the cases of leukemia in the Fallon, Nevada cluster were acute preB lymphocytic leukemia (preB ALL). 1 Normal early B-cell development proceeds within the bone marrow, where cells progress from a common lymphoid precursor through several stages to a committed B-lymphocyte that expresses rearranged immunoglobulin on the cell surface. Thus, we hypothesized that tungsten may alter developing B-cell growth. B-cell differentiation occurs within the bone marrow and tungsten accumulates within the bone, thus providing the developing B-cell with increased exposure levels of tungsten. 7 Therefore, we utilized a murine co-culture model composed of the BU-11 early pro/preB-cell line grown upon the BMS2 bone marrow stromal cell line. This model was used previously to dissect the molecular mechanisms of developing B-cell apoptosis by other environmental contaminants, such as polycyclic aromatic hydrocarbons and phthalates. 8 BU-11/BMS2 cultures were treated for 48 h with varying concentrations of tungsten and the non-adherent BU-11 cells were quantified. The highest concentration of tungsten used to treat BU-11/BMS2 cultures (500 mg/ml) is half of the highest concentration found in the environment in Fallon, NV, USA (934 p.p.m. ¼ 934 mg/ml).
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Tungsten exposure resulted in a dose and time-dependent decrease in the number of BU-11 cells (Figure 1a ). In addition, tungsten-induced changes in cell cycle and apoptosis were determined by propidium iodide staining of BU-11 cells. At 24 h, BU-11 cells treated with 500 mg/ml tungsten had a higher percentage of cells in the G 0 /G 1 phase of the cell cycle and decreased G2/M phase as compared with controls ( Figure 1c Polycyclic aromatic hydrocarbon-induced pro/preB cell apoptosis is dependent upon a death signal generated within the stromal cell. This was effectively demonstrated using BU-11 cells cultured in rIL-7 in the absence of stromal cells. Therefore, we tested whether tungsten-induced BU-11 cell death was dependent upon stromal cells. BU-11 cells grown in rIL-7 were sensitive to tungsten-induced growth inhibition and apoptosis, indicating that BU-11 cells died in a cell-autonomous manner ( Figure 1) .
We also tested whether growth of BMS2 stromal cells was altered after a 48 h exposure to tungsten using the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. As compared with BU-11 cells, BMS2 cells required higher concentrations of tungsten in order to inhibit cell growth (Supplementary Figure 1) . Whereas 250 mg/ml tungsten treatment results in a greater than 50% decrease in BU-11 cell viability, this amount of tungsten decreases BMS2 viable cell number by only 25% (Figure 1a ). This suggests that the developing B cells are more sensitive to the growthinhibitory effects of tungsten than the cells in the surrounding bone marrow microenvironment. In contrast to BU-11 cells, growth inhibition seen at 48 h was not preceded by either DNA fragmentation or caspase activity at 24 h (Supplementary Figures  1b and c) . Only after 48 h were significant increases in both apoptotic markers seen, and even then, the extent of DNA fragmentation was significantly less than in BU-11 cells (maximally 12% in BMS2 as compared with 30-50% in BU-11). Interestingly, BMS2 cells treated with tungsten increased the percentage of cells in the G2/M phase of cell cycle, while decreasing the percentage of cells in G0/G1 (Supplementary Figure 2d) . Thus, tungsten induced different cell cycle changes in the stromal cells as compared with the BU-11 cells.
To confirm these results from cloned cell lines, we tested the effects of tungsten in primary murine bone marrow-derived developing B lymphocytes. Primary bone marrow cultures were established for 1 week in media containing rIL-7. In these cultures, 485% of the non-adherent cells stained positive for the B-cell marker B220/CD45R (Figure 2a ). Previously published reports show that these cells are the proB cell subtype and respond to environmental contaminants similarly to what is observed in vivo. 8 Total bone marrow cultures were treated for 24 h with varying concentrations of tungsten. ProB cells were removed and the percentage of cells undergoing apoptosis was (Figure 2c ). Increasing concentrations of tungsten induced significant apoptosis, even at the lowest doses (50-100 mg/ml), after only 24 h of exposure. This suggests that primary B lymphocytes are more sensitive than the cloned cell lines to the effects of tungsten.
Tungsten alloys can induce DNA damage, 9 which could promote leukemogenesis. Therefore, we assessed whether tungsten alone induced DNA damage in BU-11 cells and in proB lymphocytes from primary murine bone marrow cultures. First, we utilized the alkaline COMET assay (single cell gel electrophoresis), where the extent of DNA strand breaks is a reflection of the COMET tail moment, a calculation that takes into account the length, width and intensity of the tail with respect to the head of the COMET. Cell cultures were treated with vehicle control or varying concentrations of tungsten. The non-adherent B cells were removed and COMET assays were performed. In all cells tested, tungsten induced a significant increase in the COMET tail moment, indicating an increase in DNA breaks (Figure 3a) . Importantly, in primary proB cells, treatment with as low as 10 mg/ml tungsten for 6 h significantly increased the extent of DNA damage (Figure 3a) . Figure 1 Tungsten inhibits the growth of BU-11 pro/preB cell line. BU-11 cells were grown in a co-culture with BMS2 stromal cells (left) or in rIL-7 (right). Cultures were treated with vehicle control or 50-500 mg/ml tungsten for 48 h and the number of viable BU-11 cells enumerated after trypan blue staining (a, b). After 24 h of treatment, cells were stained with propidium iodide and the cell cycle profile (c, d) and percentage of apoptotic cells (e, f) were assessed. Tungsten-induced apoptosis was confirmed at 48 h by measuring caspase 3/7 activity using Caspase-Glo assays (g, h). 
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Here, DNA damage is seen at a dose and time where no markers of cell death are increased (data not shown), indicating that DNA damage occurs independently of apoptosis and at lower doses. We confirmed our COMET assay data with western blotting experiments using antibodies against gH2AX, a phosphorylated histone variant that is induced upon DNA damage. Tungsten treatment for 6 h increased the expression of gH2AX in a dose-dependent manner in all cell types tested (Figure 3b) . Indeed, we see that the same low doses used in the COMET assays induced gH2AX expression in the primary proB cells.
Tungsten in the environment forms large complexes in the form of polytungstates, which are found in the aquatic and terrestrial ecosystems. 10 Polytungstates self-assemble under acidic conditions, and the reverse reaction is much slower, potentially leading to the accumulation of these tungsten complexes. Therefore, we compared the toxicity of tungsten with that of one polytungstate, metatungstate. BU-11/BMS2 cultures were treated for 48 h comparing equivalent concentrations of elemental tungsten. Subsequently, we assessed BU-11 cell growth. Metatungstate inhibited the growth and induced apoptosis in the BU-11 cells to the same degree as tungsten, suggesting that multiple forms of tungsten may have similar growth-inhibitory effects on developing B lymphocytes (Supplementary Figure 2a ). In addition, we compared the ability of tungsten and metatungstate to induce gH2AX expression by immunoblotting in either BU-11 cells grown on BMS2 or B lymphocytes from primary bone marrow cultures. After 6 h, both compounds induced gH2AX, although metatungstate induced higher expression (Supplementary Figure 2B) .
The in vitro data presented above suggest that the developing hematopoietic compartment may be sensitive to tungsteninduced changes. To determine whether in vivo exposure to tungsten might induce DNA damage within the bone marrow compartment, we exposed C57BL/6J wild-type mice to tungsten in the drinking water (15 mg/ml or 200 mg/ml) for 8 weeks. These doses correspond to the lower and higher doses used in our in vitro work where DNA damage was observed (Figure 3a) . While tungsten did not significantly alter that total bone marrow cellularity at these concentrations (Figure 4a ), we found that tungsten exposure resulted in an increase in DNA damage as assessed by COMET assay (Figure 4b ).
Together these data provide the first evidence that pro/preB lymphocytes are targets for tungsten-induced toxicity, and that tungsten exposure may result in DNA damage within this cellular compartment. In the present study, we chose to use tungsten concentrations (934 p.p.m.E1 g/l) representing the surface dust 'hot spot' found in Fallon 11 as the highest dose in our dose range. Previously, others have utilized this dose range to investigate the effects of tungsten exposure in vitro on peripheral blood mononuclear cells. 4 Indeed, this high dose was extremely toxic to the pro/preB lymphocytes (data not shown), whereas this dose only slightly increased markers of late apoptosis in peripheral blood lymphocytes. 4 Treatment with half of this dose (500 mg/ml) resulted in a significant growth inhibition and 35-40% apoptosis in BU-11 cells (Figure 1 ) and 75% apoptosis in primary bone marrow cultures (Figure 2 ). This is in contrast to BMS2 stromal cells, which were less sensitive to tungsten-induced apoptosis (Supplementary Figure 1) . Together these data suggest that the developing B-cell compartment may be sensitive to tungsten exposure. Although the doses tested here are likely to be above the environmental exposure, 2 the accumulation of tungsten in the bone indicates that the bone marrow, and therefore hematopoietic cells undergoing differentiation, may be exposed to higher levels of tungsten. Indeed, tungsten accumulation in the spleen and bone ranges from 2 to 70 p.p.m. (2-70 mg/ml) after 28 days of in vivo exposure to 62.5-200 mg/kg per day. 12 We estimate that, in our in vivo study, mice given 15 and 200 mg/ml tungsten received 3.75 and 50 mg/kg per day, slightly lower than the doses previously described. 12 Further testing is required to determine the effects of long-term, low-dose tungsten exposure to early B cells in vitro and in vivo.
Our in vivo investigations are particularly intriguing and show that oral tungsten exposure can result in DNA damage within the bone marrow. Further studies are required to determine which cells within the bone marrow are targets for tungsten-induced DNA damage and whether B-cell development is altered. In addition, we see that in vivo exposure to as little as 15 mg/ml tungsten induces DNA damage. Although this approaches the highest tap water concentrations measured in Fallon (.290 mg/ml), 13 we need to investigate the effects of lower tungsten concentrations in our model. Finally, we will determine whether tungsten can act, via DNA damage or apoptosis, as a leukemogenic agent in murine leukemia models. This would confirm that tungsten is not an inert metal, but rather has the potential to have serious adverse health effects. These data also have important implications for other tungsten exposures, such as tungsten alloys used in ammunition and tungsten-based therapies for diabetes currently in clinical trials.
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The authors declare no conflict of interest. Mutation of the TP53 gene at chromosome band 17p13 is the single most common genetic alteration found in human cancer, although the prevalence of TP53 mutations is considerably lower in hematological malignancies (o20%) compared with solid tumors (450%). 1 Nevertheless, TP53 mutations have been reported to be associated with poor prognosis in hematological malignancies, such as diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). 1 Furthermore, the profile of TP53 mutations appears to vary between different cancers, and a relationship has been found between certain carcinogens and specific mutation types. 2 Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin's lymphoma characterized by the t(11;14)(q13;q32), leading to cyclin D1 overexpression. MCL displays a high degree of genomic instability, reflected by a large number of secondary aberrations, and has an average survival of only 4-5 years. 3 However, the TP53 gene, which is an essential gene for genomic integrity, has not been extensively studied in MCL, although TP53 mutations have been reported more frequently in the clinically aggressive blastoid variant. 1 In one of the larger reports from the Leukemia and Lymphoma Molecular Profiling Project (LLMPP), TP53 mutations were found in 16/82 (20%) of MCL samples and were associated with an unfavorable clinical course. 4 That notwithstanding, the prognostic relevance of 17p deletions (which include the TP53 gene) in MCL is less clear, although several studies have indicated an association with short survival. 5 The aim of this study was to further investigate the mutation profile and prognostic impact of TP53 mutations and 17p deletion in a large cohort of 119 MCL patients collected at university hospitals in Sweden and Finland between 1983 and 2004 (median 1999). All cases fulfilled the World Health Organization diagnostic criteria for MCL, including overexpression of cyclin D1 and/or the presence of t(11;14)(q13;q32) as determined by immunostaining and fluorescence in situ hybridization, respectively. 6 Tumor samples were mainly obtained from lymph nodes, but also from spleen, tonsils, bone marrow or other tissues. The median age at diagnosis was 68 years (range, 45-97 years), the male:female ratio 3:1 and the median overall survival (OS) for the entire cohort was 36 months. Of the 118 cases with available histological data, 84 had classic MCL and 34 the blastoid variant. As expected, OS was significantly shorter among blastoid MCL cases than among classic MCL cases (median 24 vs 39 months, P ¼ 0.01, log rank test).
For the purpose of TP53 mutation detection, exons 4-8 of the TP53 gene were PCR amplified using genomic DNA and purified before sequencing as previously described. 7 These
